Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Lambert-Eaton myasthenic syndrome Indication Strategy Report 2026: VGCC, Trials and Deals
23 July 2026
2026 Lambert-Eaton myasthenic syndrome strategy: epidemiology, VGCC biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Stiff person syndrome Indication Strategy Report 2026: GAD65, Trials and Deals
23 July 2026
2026 Stiff person syndrome strategy: epidemiology, GAD65 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Neuromyotonia Indication Strategy Report 2026: CASPR2, Trials and Deals
23 July 2026
2026 Neuromyotonia strategy: epidemiology, CASPR2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Primary angiitis of the central nervous system Indication Strategy Report 2026: IL-6, Trials and Deals
23 July 2026
2026 Primary angiitis of the central nervous system strategy: epidemiology, IL-6 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Adult-onset leukoencephalopathy with axonal spheroids Indication Strategy Report 2026: CSF1R, Trials and Deals
23 July 2026
2026 Adult-onset leukoencephalopathy with axonal spheroids strategy: epidemiology, CSF1R biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Post-polio syndrome Indication Strategy Report 2026: IGF-1, Trials and Deals
23 July 2026
2026 Post-polio syndrome strategy: epidemiology, IGF-1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Progressive muscular atrophy Indication Strategy Report 2026: SOD1, Trials and Deals
23 July 2026
2026 Progressive muscular atrophy strategy: epidemiology, SOD1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Primary lateral sclerosis Indication Strategy Report 2026: SOD1, Trials and Deals
23 July 2026
2026 Primary lateral sclerosis strategy: epidemiology, SOD1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Unverricht-Lundborg disease Indication Strategy Report 2026: CSTB, Trials and Deals
23 July 2026
2026 Unverricht-Lundborg disease strategy: epidemiology, CSTB biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Spinal and bulbar muscular atrophy Indication Strategy Report 2026: Androgen receptor, Trials and Deals
23 July 2026
2026 Spinal and bulbar muscular atrophy strategy: epidemiology, Androgen receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Lafora disease Indication Strategy Report 2026: GYS1, Trials and Deals
23 July 2026
2026 Lafora disease strategy: epidemiology, GYS1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Progressive myoclonic epilepsy Indication Strategy Report 2026: GABA-A receptor, Trials and Deals
23 July 2026
2026 Progressive myoclonic epilepsy strategy: epidemiology, GABA-A receptor biology, clinical competition, recent deals, unmet need and market attractiveness.